Form S-8 - Securities to be offered to employees in employee benefit plans:
SEC Accession No. 0001193125-25-180815
Filing Date
2025-08-14
Accepted
2025-08-14 16:28:49
Documents
16
Effectiveness Date
2025-08-14

Document Format Files

Seq Description Document Type Size
1 S-8 d75109ds8.htm S-8 31530
2 EX-5.1 d75109dex51.htm EX-5.1 11884
3 EX-23.1 d75109dex231.htm EX-23.1 1225
4 EX-FILING FEES d75109dexfilingfees.htm   iXBRL EX-FILING FEES 16635
5 GRAPHIC g75109dsp7.jpg GRAPHIC 6311
6 GRAPHIC g75109dsp8.jpg GRAPHIC 3879
  Complete submission text file 0001193125-25-180815.txt   204791

Data Files

Seq Description Document Type Size
18 EXTRACTED XBRL INSTANCE DOCUMENT d75109dexfilingfees_htm.xml XML 8028
Mailing Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010
Business Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010 212-994-8250
MiNK Therapeutics, Inc. (Filer) CIK: 0001840229 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: S-8 | Act: 33 | File No.: 333-289606 | Film No.: 251219828
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)